Why Roche Holding (SWX:ROP) Is Getting Attention Today

Roche Holding (SWX:ROP) has been back in focus after Treeline Biosciences agreed to a clinical trial collaboration that combines TLN-121 with Roche bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Roche Holding shares trade at CHF357.0, with a 90-day share price return of 10.63% and a year-to-date share price return of 9.68%. The 1-year total shareholder return of 34.18% points to momentum that has built alongside a steady stream of oncology and diagnostics...